
Aytu BioScience (AYTU) Stock Forecast & Price Target
Aytu BioScience (AYTU) Analyst Ratings
Bulls say
Aytu BioPharma is supported by an improving operating profile, with fiscal Q4 FY26 revenue of $16.1 million, up 6% year over year and well ahead of estimates, while pro forma EPS of $0.03 beat expectations by a wide margin. The company’s outlook is anchored by EXXUA, a first-in-class FDA-approved treatment for adult MDD that launched in Q4 2025 and has shown a highly encouraging early reception, backed by a differentiated side-effect profile and clinical data from more than 5,000 patients. With EXXUA targeting the $22 billion U.S. prescription MDD market and management’s conservative FY27 revenue expectations of $68 million to $70 million, the stock offers meaningful growth leverage if commercialization continues to gain traction.
Bears say
Aytu BioPharma is facing a weak fundamental backdrop, as fiscal Q3 FY26 revenue fell 33% year over year to $12.4 million, highlighting sharp top-line deterioration despite narrowly beating estimates of $12.0 million and consensus of $12.1 million. Profitability remains under pressure, with pro forma EPS of $(0.43) coming in worse than the estimate of $(0.31), underscoring that losses are still widening or proving difficult to contain. The lack of Q3 guidance adds to the negative outlook because it limits visibility into near-term execution and suggests management may not have confidence in an immediate turnaround.
This aggregate rating is based on analysts' research of Aytu BioScience and is not a guaranteed prediction by Public.com or investment advice.
Aytu BioScience (AYTU) Analyst Forecast & Price Prediction
Start investing in Aytu BioScience (AYTU)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Aytu BioScience (AYTU) Forecast
Aytu BioScience (AYTU) Analyst Forecast & Price Prediction
Start investing in Aytu BioScience (AYTU)
Order type
Buy in
Order amount
Est. shares
0 shares